Intubating Condition After Magnesium Pre-treatment

Not Applicable

Completed

• Conditions: Easy of Laryngoscopy Manipulation; Vocal Cord Position or Movement; Patient Reaction to Intubation and Cuff Inflation; Mean Arterial Pressure; Heart Rate
• Interventions: Drug: normal saline; Drug: magnesium sulphate

• Registration Number: NCT01153256
• Lead Sponsor: Seoul National University Bundang Hospital

Brief Summary

Magnesium had an inhibitory effect on neuromuscular transmission and caused a decrease in muscle fiber membrane excitability. It reduces the amount of acetylcholine that is released at the motor nerve terminal by decreasing the calcium conductance of presynaptic voltage-dependent calcium channels. After pre-treatment with magnesium, an increased speed of onset and a prolongation of the recovery period of neuromuscular blockade have been observed with other non-depolarizing neuromuscular blocking agent (NMBA) such as atracurium, vecuronium and rocuronium. Rocuronium is the currently preferred NMBA used as an alternative to succinylcholine for rapid tracheal intubation. As an alternative to succinylcholine, high doses of NMBA have been tested for rapid sequence intubation. This excessively high dose of rocuronium, however, prolongs the duration of the neuromuscular block and this may not be warranted in every surgical setting.

The reduction of onset time of rocuronium by magnesium pre-treatment can make intubation condition more rapid and much better clinically. It will thus be interesting to compare intubation conditions of a standard intubation dose of rocuronium after magnesium pre-treatment with high dose of rocuronium or standard dose of rocuronium.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2010-04-09
• Study First Submitted QC: 2010-06-29
• Study First Posted: 2010-06-30
• Study Start: 2010-12
• Primary Completion: 2011-03
• Study Completion: 2011-03
• Status Verified: 2012-01
• Last Update Submitted: 2012-01-06
• Last Update Posted: 2012-01-09

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

• patients undergoing operation under general anesthesia
• American Society of Anesthesiologist physical status I or II
• 20-65 year old male or female

Exclusion Criteria

• hepatic or renal dysfunction
• respiratory or cardiovascular dysfunction
• neurologic disorder
• neuromuscular disease
• pregnancy
• body mass index (BMI) >30 kg/m2 or <16.5 kg/m2
• anticipated difficult airway
• higher magnesium level than normal range in preoperative evaluation
• chronic medication with calcium channel blocker or magnesium
• history of known allergy to magnesium sulphate or any other study drugs

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group R-0.6	normal saline	-
Group R-0.9	normal saline	-
group M	magnesium sulphate	-

Primary Outcome Measures

Name	Time	Method
the intubating conditions	1 minute during intervention	The anesthesiologist also assessed the intubating conditions as per the intubation scoring system of the Good Clinical Research Practice guideline.

Secondary Outcome Measures

Name	Time	Method
mean arterial pressure (MAP)	5 min before intubation, immediate before intubation, post-intubation 1, 2, 3, 4, and 5 min.	They were recorded pre-induction (base line), just before intubation, and every minute thereafter for 5 min.
heart rate (HR)	5 min before intubation, immediate before intubation, post-intubation 1, 2, 3, 4, and 5 min.	They were recorded pre-induction (base line), just before intubation, and every minute thereafter for 5 min.

Trial Locations

Locations (1)

Seoul National University Bundang Hospital; 🇰🇷 Seongnam-si, Gyeonggi-do, Korea, Republic of